Differential Expression of microRNAs in Acute and Chronic Heart Failure.

Acute heart failure B-type natriuretic peptide biomarkers chronic heart failure differential expression miRNA

Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
15 Aug 2022
Historique:
received: 28 12 2021
revised: 23 02 2022
accepted: 09 03 2022
pubmed: 28 4 2022
medline: 20 8 2022
entrez: 27 4 2022
Statut: ppublish

Résumé

MicroRNAs modify protein expression at the post-transcriptional level, and their circulating levels may help identify the underlying molecular pathways. The purpose of this study was to assess the differential expression of microRNAs related to myocardial cell energy substrate, autophagy, and ischaemia in chronic and acute heart failure (HF). In this case-control study, we studied 19 patients with acute HF (AHF) and 19 patients with chronic HF (CHF). Basic demographic and clinical characteristics were collected from the patients upon arrival, at 48 hours, and at 120 hours. Blood samples for microRNAs measurements (miR-22, -92a, and -499), B-type natriuretic peptide (BNP), C reactive protein, and high sensitivity cardiac troponin I, were collected at all study points. In this study, we included subjects with a left ventricular ejection fraction of <40%. At baseline, circulating miR-22 levels were 1.9-fold higher (p<0.001), miR-92a levels were 1.25-fold higher (p=0.003), and miR-499 were 5-times lower (p<0.001) in AHF compared to CHF. Interestingly, circulating miR-499 was found to be associated with BNP levels (r=0.47, p=0.01). At follow-up, there was a stepwise increase in the levels of all three examined microRNAs (miR-22, p=0.001, miR-92a, p=0.001, and miR-499, p<0.001) for AHF but not for CHF subjects. MicroRNAs -22, -92a, and -499 are differentially expressed in chronic and acute HF subjects. MicroRNA signatures are also differentially expressed up to the discharge of the patients. These findings may have important implications for diagnosis, progression, and treatment of patients with chronic and acute heart failure.

Sections du résumé

BACKGROUND BACKGROUND
MicroRNAs modify protein expression at the post-transcriptional level, and their circulating levels may help identify the underlying molecular pathways.
OBJECTIVE OBJECTIVE
The purpose of this study was to assess the differential expression of microRNAs related to myocardial cell energy substrate, autophagy, and ischaemia in chronic and acute heart failure (HF).
METHODS METHODS
In this case-control study, we studied 19 patients with acute HF (AHF) and 19 patients with chronic HF (CHF). Basic demographic and clinical characteristics were collected from the patients upon arrival, at 48 hours, and at 120 hours. Blood samples for microRNAs measurements (miR-22, -92a, and -499), B-type natriuretic peptide (BNP), C reactive protein, and high sensitivity cardiac troponin I, were collected at all study points. In this study, we included subjects with a left ventricular ejection fraction of <40%.
RESULTS RESULTS
At baseline, circulating miR-22 levels were 1.9-fold higher (p<0.001), miR-92a levels were 1.25-fold higher (p=0.003), and miR-499 were 5-times lower (p<0.001) in AHF compared to CHF. Interestingly, circulating miR-499 was found to be associated with BNP levels (r=0.47, p=0.01). At follow-up, there was a stepwise increase in the levels of all three examined microRNAs (miR-22, p=0.001, miR-92a, p=0.001, and miR-499, p<0.001) for AHF but not for CHF subjects.
CONCLUSION CONCLUSIONS
MicroRNAs -22, -92a, and -499 are differentially expressed in chronic and acute HF subjects. MicroRNA signatures are also differentially expressed up to the discharge of the patients. These findings may have important implications for diagnosis, progression, and treatment of patients with chronic and acute heart failure.

Identifiants

pubmed: 35473531
pii: CMC-EPUB-122889
doi: 10.2174/0929867329666220426095655
doi:

Substances chimiques

Biomarkers 0
MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5130-5138

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Aimilios Kalampogias (A)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Evangelos Oikonomou (E)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
3rd Department of Cardiology, "Sotiria" Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Gerasimos Siasos (G)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
3rd Department of Cardiology, "Sotiria" Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Panagiotis Theofilis (P)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Stathis Dimitropoulos (S)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Maria Gazouli (M)

Laboratory of Biology of Medical School of National and Kapodistrian University of Athens, Athens, Greece.

Vasiliki Gennimata (V)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Georgios Marinos (G)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Georgios Charalambous (G)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Manolis Vavouranakis (M)

3rd Department of Cardiology, "Sotiria" Chest Disease Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Konstantinos Tsioufis (K)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Dimitris Tousoulis (D)

1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH